Last $5.71 USD
Change Today +0.06 / 1.06%
Volume 30.1K
TROV On Other Exchanges
As of 10:48 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

trovagene inc (TROV) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/29/14 - $7.10
52 Week Low
08/1/14 - $2.97
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TROVAGENE INC (TROV)

trovagene inc (TROV) Related Bloomberg News

View More Bloomberg News

trovagene inc (TROV) Related Businessweek News

No Related Businessweek News Found

trovagene inc (TROV) Details

Trovagene, Inc. develops its proprietary technology for the detection and monitoring of circulating tumor DNA in both urine and blood. Its technology detects and quantitates oncogene mutations in cancer patients for improved disease management. The company’s Precision Cancer Monitoring platform is designed to provide clinical information, such as response to treatment and resistance to therapy from a simple urine or blood sample. Its technology for the detection and monitoring of cell-free DNA in urine could be applied in various disease settings, such as infectious disease, transplantation monitoring, and prenatal genetic diagnostics. Trovagene, Inc. has a clinical collaboration with Genomac Research Institute to demonstrate clinical utility in lung and colorectal cancer treatment monitoring. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

25 Employees
Last Reported Date: 11/6/14
Founded in 1999

trovagene inc (TROV) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $533.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $333.8K
Chief Scientific Officer
Total Annual Compensation: $269.7K
Compensation as of Fiscal Year 2013.

trovagene inc (TROV) Key Developments

TrovaGene, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015

TrovaGene, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

Trovagene, Inc. Announces Presentation of Clinical Results from the PREDICTORS 4 Trial

Trovagene, Inc. announced the presentation of clinical results from the PREDICTORS 4 trial, which demonstrate high sensitivity for the Company's non-invasive, urine-based HPV assay when determining high-risk human papillomavirus (HPV) types and cervical lesions or cervical intraepithelial neoplasia (CIN) Grade 2/3. Jack Cuzick, Ph.D., Director, Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention at Queen Mary University of London, presented the study results at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) 2015 Congress in Sevilla, Spain. Within the PREDICTORS 4 trial, urine and cervical samples were collected from 501 women, and data from this large patient subset demonstrated that sensitivity with Trovagene's HPV assay for cervical samples was comparable to established cervical screening tests. Sensitivity of the Trovagene HPV assay using cervical samples was 96.3% for CIN Grade 3+ and 94.5% for CIN Grade 2+. Sensitivity for urine samples was 91.4% for CIN Grade 3+ and 89.0% for CIN Grade 2+. Furthermore, detection of high risk HPV in urine was not different from cervical samples for all age groups of women in the study (18-29 yrs, 30-39 yrs and 40-69 yrs). The study authors concluded that while there is a small loss of sensitivity in urine, the greater than 90% sensitivity for CIN Grade 3+ is still better than conventional Pap cytology, which makes this assay a good candidate to increase adoption of HPV testing, especially for women who are not currently being screened for cervical cancer.

TrovaGene, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 03:30 PM

TrovaGene, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 03:30 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Antonius P. Schuh, Chief Executive Officer and Director, Stephen L. Zaniboni, Chief Financial Officer and Principal Accounting Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TROV:US $5.71 USD +0.06

TROV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $44.50 USD +0.30
Genomic Health Inc $30.77 USD +0.371
Laboratory Corp of America Holdings $123.78 USD +0.75
Veracyte Inc $8.82 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation TROV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 393.9x
Price/Book 8.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 319.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TROVAGENE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at